Connect
← Return to Pancreatic Cancer Surgery Q&A w/ Dr. Stauffer on September 4
Discussion
Pancreatic Cancer Surgery Q&A w/ Dr. Stauffer on September 4
Pancreatic Cancer | Last Active: Sep 7 9:38am | Replies (33)Comment receiving replies
I read that rmc6236 which is named as ras solute 302 in phase 3 was given the designation of FDA breakthrough therapy in late June of this year. All trials will be completed by the end of this year. FDA approval to occur in 2026. Do you have any idea when in 2026 this approval should be given?
Replies to "I read that rmc6236 which is named as ras solute 302 in phase 3 was given..."
Connect
Correction: enrollment in phase 3 will be completed by the end of this year. So if trials are still going on in 2026, and since this drug (6236) has the FDA designation of breakthrough therapy, what is the likelihood FDA will approve it in 2026?